Quotient Ltd

Delisted

CIK 1596946fmd_13VVZXTXGMR618RBJW0C27HK3CManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard

Coverage: Apr 01, 2012 to Dec 31, 2022, 40 periods

Income Statement · Annual · Millions · USD
Line item	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022
Total revenues	14	20	18	19	22	25	29	33	43	39
Cost of revenue	7	8	10	10	11	10	17	18	20	24
Gross profit	7	11	9	9	11	14	12	15	23	15
Research and development	3	8	19	29	57	51	51	53	54	59
Selling, general and administrative	9	12	19	29	28	33	40	42	52	60
Total operating expenses	12	20	38	58	85	84	91	95	106	119
Operating income	(4)	(9)	(30)	(49)	(74)	(70)	(79)	(80)	(83)	(104)
Other non-operating income (expense)	(0)	(1)	(29)	15	(11)	(13)	(27)	(25)	(27)	(20)
Income before taxes	(5)	(10)	(59)	(34)	(85)	(83)	(106)	(105)	(110)	(124)
Income tax expense	–	–	–	–	–	(1)	0	0	1	1
Net income from continuing operations	–	–	–	–	–	(82)	(106)	(105)	(111)	(125)
Net income	(5)	(10)	(59)	(34)	(85)	(82)	(106)	(105)	(111)	(125)
Net income to common shareholders	(5)	(10)	(59)	(34)	(85)	(82)	(106)	(105)	(111)	(125)